Screener
UroGen Pharma URGN Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and Shareholders' Deficit | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $39,945 | $27,717 |
| Employee related accrued expenses | 12,253 | 13,516 |
| Current liabilities related to finance leases | 1,411 | 1,274 |
| Current liabilities related to operating leases | 684 | 481 |
| Other current liabilities | 7,622 | 3,430 |
| Total current liabilities | 61,915 | 46,418 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's accrued expenses?
- UroGen Pharma (URGN) reported accrued expenses of $12.25M in Q2 2026.
- How has UroGen Pharma's accrued expenses changed year-over-year?
- UroGen Pharma's accrued expenses increased by 5.2% year-over-year, from $11.65M to $12.25M.
- What is the long-term trend for UroGen Pharma's accrued expenses?
- Over 5 years (2020 to 2025), UroGen Pharma's accrued expenses has grown at a 7.2% compound annual growth rate (CAGR), from $9.55M to $13.52M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about UroGen Pharma's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude